Current Treatment for Benign Prostatic Hyperplasia

Dtsch Arztebl Int. 2020 Dec 4;117(49):843-854. doi: 10.3238/arztebl.2020.0843.

Abstract

Background: Benign prostatic hyperplasia (BPH) is characterized by the occurrence of.disorders of urine storage and bladder emptying. Most men over the age of 60 years are affected to some degree.

Methods: A selective literature search with additional scrutiny of guidelines and meta-analyses.

Results: The management of patients with BPH is complex. Emptying and retention disorders can be treated by various pharmacological and surgical means. Transurethral resection of the prostate (TURP) has long been considered the gold standard for operative treatment. Transurethral enucleation procedures show a better risk profile in some uses, however, and have, above all, largely displaced suprapubic prostatectomy. Numerous innovative treatment options have been developed in recent years, but their long-term effects remain to be determined. These treatment techniques can nevertheless be used in individual cases after thorough discussion with the patient.

Conclusion: The care of patients with BPH should be interdisciplinary. The efficacy and safety of many new developments in the area of pharmacological and minimally invasive treatment remain to be demonstrated in randomized trials.

Publication types

  • Review

MeSH terms

  • Humans
  • Laser Therapy*
  • Male
  • Middle Aged
  • Prostatectomy
  • Prostatic Hyperplasia* / diagnosis
  • Prostatic Hyperplasia* / surgery
  • Transurethral Resection of Prostate*
  • Treatment Outcome